Showing 301-310 of 2216 results for "".
Movement Disorders Moment: Personalized Medicine in Parkinson Disease
https://practicalneurology.com/archives/aug-2025-issue/personalized-medicine-in-parkinson-disease/36699/Pharmacogenetic testing provides a promising path to personalizing treatments for individuals living with Parkinson disease.The Whole Physician: Physicians with Substance Use Disorder: Help Is Available
https://practicalneurology.com/columns/practice-management/the-whole-physician-physicians-with-substance-use-disorder-help-is-available/32059/Support is available for physicians with substance use disorder, allowing them to return to health and their profession.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31019/Optimizing Restless Legs Syndrome Treatment: Insights from Recent Meta-Analysis and Clinical ExperiencesA recent meta-analysis evaluating the side effects and wearing-off effects of four Restless Legs Syndrome (RLS) medications highlighted significant findings relevant to clinical practice. The stud
- Second Opinionshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0505SecondOpinion-pdf/31458/Addressing the AD-VaD Diagnostic Challenge in NeurologyIn the debate surrounding Alzheimer’s Disease (AD) versus vascular dementia (VaD) diagnosis, Dr. Geldmacher’s April 2005 article, “Diagnosing Alzheimer’s: Easy Answers vs. Right Answers,” ignited significant discourse. Dr. Geldmacher critiques c
Dementia Insights: Language and Dementia
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/dementia-insights-language-and-dementia/31697/Who can take us seriously when we are so far from who we once were?; Everything she did and loved, everything she was, required language. -Lisa Genova, Still Alice.Neuromuscular Notes: Next Generation Treatments for Myasthenia Gravis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/neuromuscular-notes-next-generation-treatments-for-myasthenia-gravis/31666/Complement inhibitors, FcRn antagonists, and B-cell targeted therapies increase treatment options for MG but do not replace existing immunosuppressive therapies.Porphyric Neuropathy
https://practicalneurology.com/diseases-diagnoses/neuromuscular/porphyric-neuropathy/31689/Timely diagnosis and treatment and new medications to prevent attacks provide more options for treating acute hepatic porphyrias.Managing Uncertainty in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/managing-uncertainty-in-multiple-sclerosis/31877/Multiple sclerosis creates a constant uncertainty-driven challenge that can threaten function, well-being, and quality of lifeCladribine
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/cladribine/31631/Cladribine is an effective oral treatment for multiple sclerosis with potential for long-term remission.Noninflammatory Myopathies
https://practicalneurology.com/diseases-diagnoses/neuromuscular/noninflammatory-myopathies/31557/As genetic diagnosis increases, noninflammatory myopathies are being seen more in clinical practice.